Chronic Obstructive Pulmonary Disease (COPD) - Drug Pipeline Analysis and Market Forecasts to 2016
This report provides the key data, information and analysis on the COPD market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast forward seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with COPD, competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for future market competition, and the key players in the COPD market. ( http://www.bharatbook.com/
The COPD Market is Forecast to Show Positive Growth until 2016
It estimated the chronic obstructive pulmonary disease (COPD) market to be worth $7.2 billion in 2009 and projects it to grow at a compound annual growth rate (CAGR) of 7.4% to reach $11.9 billion in 2016. The development of novel once-daily inhaled therapies is expected to provide new treatment options for COPD patients worldwide, and will play a major role in the expansion of the COPD market in the coming years. A steady increase in the incidence rate, smoking population and in injurious environmental factors in most countries has caused the COPD market to grow significantly.
Big Pharmaceutical Companies Lead the Way in COPD Drug Development
It has found that Altana Pharma's Roflumilast, Almirall, S.A/Forest Lab's aclidinium bromide, GlaxoSmithKline/
Strong Pipeline with Novel First-in-Class Candidates May Significantly Improve the COPD Treatment Paradigm
It has found that the COPD developmental pipeline is strong with over 130 molecules in various phases of clinical development. There are more than 67 first-in-class molecules in different stages of clinical development. These molecules have distinct advantages over the currently marketed players. Trials are being conducted on novel mechanisms and combinational targeted therapies which may improve the symptoms of COPD and prolong the lives of COPD patients. The launch of these innovative products should lead to a decrease in the symptoms of exacerbations, improvements in lung functions and improve patients’ quality of life.
High Unmet Need Continues to Remain Unaddressed
GlobalData has found that the COPD market has high levels of unmet need. Greater unmet needs imply that the market is not well served by the current product options with boundless scope available to new entrants to capture value from underserved segments. Emerging therapies such as long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations, long-acting muscarinic antagonists (LAMAs), and LABA/LAMA, will emerge as potentially efficacious entrants over the coming years. There is a need for drugs that can dramatically reduce exacerbation rates, slow or halt the progression of COPD, and improve lung functions and the quality of life in COPD patients. Overall, the market is likely to grow rapidly with the entry of these novel combinational therapies and patient expectations are managed through more efficacious products in near future.
To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/
